Đang chuẩn bị liên kết để tải về tài liệu:
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

The treatment goal for recurrent malignant gliomas centers on disease stabilization while minimizing therapy-related side effects. Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective. |

TÀI LIỆU LIÊN QUAN

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: Study protocol

A prospective phase I study of hypofractionated neoadjuvant radiotherapy for locally advanced gastric cancer

BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: A first-inhuman phase-I study

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease smallcell lung cancer (LD-SCLC): TORG 0604

Optimal biological dose: A systematic review in cancer phase I clinical trials

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: Study protocol

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.